Table 4 Revascularization for acute arterial occlusive disease*23).
Obstructive artery*24) | Cases | Gender | Mortality | Etiology | Procedure | Graft materials for open surgery | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Male | Female | 30-day mortality | Hospital mortality | Embolism | Thrombosis*25) | Others | Thrombectomy± patch | Bypass | Replacement | PTA± stent | Others | Autogenous vessel | Polyester | ePTFE | Others | ||
Carotid artery | 3 | 2 | 1 | 2 | 2 | 1 | 2 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
Subclavian artery | 63 | 31 | 32 | 5 | 6 | 28 | 20 | 15 | 32 | 18 | 4 | 9 | 3 | 3 | 15 | 7 | 0 |
Axillar artery | 66 | 24 | 42 | 4 | 5 | 37 | 25 | 4 | 52 | 8 | 0 | 5 | 3 | 3 | 2 | 7 | 0 |
Brachial artery | 727 | 353 | 374 | 14 | 19 | 350 | 355 | 22 | 597 | 16 | 9 | 35 | 94 | 17 | 12 | 20 | 3 |
Celiac/superior mesenteric artery | 108 | 70 | 38 | 12 | 17 | 50 | 30 | 28 | 53 | 31 | 2 | 8 | 16 | 21 | 6 | 7 | 0 |
Renal artery | 17 | 10 | 7 | 2 | 2 | 5 | 2 | 10 | 2 | 3 | 0 | 6 | 6 | 1 | 2 | 0 | 0 |
Abdominal aorta–iliac artery | 723 | 501 | 222 | 76 | 99 | 260 | 371 | 92 | 430 | 210 | 17 | 141 | 35 | 15 | 120 | 112 | 5 |
Femoro–popliteal artery | 2,433 | 1,571 | 862 | 191 | 244 | 1,019 | 1,310 | 103 | 1,976 | 303 | 33 | 250 | 139 | 121 | 142 | 173 | 12 |
Crural artery | 729 | 473 | 256 | 49 | 71 | 334 | 374 | 20 | 590 | 74 | 4 | 97 | 59 | 52 | 21 | 30 | 6 |
Pedal artery | 51 | 35 | 16 | 6 | 8 | 26 | 24 | 1 | 41 | 7 | 0 | 5 | 3 | 5 | 2 | 1 | 1 |
Others | 314 | 205 | 109 | 14 | 21 | 46 | 222 | 46 | 203 | 60 | 4 | 40 | 34 | 43 | 15 | 21 | 4 |
Total | 4,600 | 2,879 | 1,721 | 310 | 404 | 1,882 | 2,401 | 316 | 3,472 | 635 | 65 | 489 | 349 | 246 | 288 | 339 | 29 |
*23) Cases with non-traumatic acute arterial occlusion are listed in this table. Please see Table 5-1 for acute arterial occlusion by trauma. *24) The most proximal occluded artery name is described in case whose primary occluded artery could not be identified. *25) Cases with acute worsening occlusion of chronic arterial occlusive disease are excluded. Treatment for those cases are listed in Table 3.